Secondary IDH mutations, IDH isoform switching, and alternative mutations in cellular differentiation pathways (e.g., TET2 and RUNX1) are known mechanisms of acquired resistance to ivosidenib in AML [99,100,101]. Here, IDH2 is linked to acute myeloid leukemia.